Dan Streja, MD
University of California, Los Angeles
Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja has expertise in the management of diabetes, hypertension, hyperlipidemia, and antithrombotic therapy. He is a consultant in Endocrinology for a large managed care medical group. Dr. Streja also serves as the Medical Director of Infosphere Clinical Research. Previously, he was a Professor of Physiology at the University of Manitoba and specialized in the biochemistry of lipids and carbohydrate metabolism. Dr. Streja is a consultant for Abbott, BMS, Bayer, Eli-Lilly, Merck, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Pfizer, Roche, and Sankyo. (This is me - Update Profile)
| 1979 - present | Consultant Endocrinologist Affiliates In Medical Specialties Medical Group, Inc |
|---|---|
| 1979 - present | Clinical Professor of Medicine University of California, Los Angeles |
| 1979 - present | Co-director VA MEDICAL CENTER |
GLG Study Groups with Dan Streja, MD(?)
| Study Group Name | Members |
|---|---|
| Non-Electrophysiologist Cardiologists (US) | 832 |
| Cardiologists Specializing in Lipids (US) | 162 |
| General Cardiologists (US) | 1333 |
| Endocrinologists (US) | 636 |
GLG NewsSM Analyses by Dan Streja, MD(?)
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal...
GLG InstituteSM Seminars with Dan Streja, MD(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Dan Streja, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

